|
Jun 20
|
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
|
|
May 29
|
Alcon Stock Rises Following the FDA Approval of TRYPTYR
|
|
May 29
|
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease
|
|
May 28
|
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
|
|
Mar 13
|
Alcon to Host 2025 Capital Markets Day
|
|
Mar 13
|
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
|
|
Feb 24
|
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
|
|
Feb 19
|
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
|
|
Dec 31
|
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
|
|
Jun 24
|
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
|
|
Jun 24
|
Alcon obtains FDA 510(k) approval for Unity VCS and CS systems
|
|
Jun 24
|
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
|
|
Apr 7
|
Alcon Publishes Agenda for 2024 Annual General Meeting
|
|
Apr 3
|
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
|
|
Apr 3
|
Investing in Alcon (VTX:ALC) five years ago would have delivered you a 29% gain
|
|
Jan 10
|
Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials
|
|
Jan 9
|
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
|
|
Jan 5
|
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
|
|
Jan 4
|
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
|
|
Dec 27
|
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
|